This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
Biogen Idec Inc. (BIIB - Analyst Report) is slated to announce its second quarter results on Tuesday, July 24, before the opening bell. The Zacks Consensus Estimate for the second quarter is $1.56 per share, 14.7% above the year-ago earnings of $1.36.
First Quarter Highlights
Biogen reported first quarter earnings per share of $1.39, below the Zacks Consensus Estimate of $1.44 and the year-ago earnings of $1.42. Results were affected by higher costs. First quarter 2012 revenues, which were in-line with the Zacks Consensus Estimate, increased 7% to $1.3 billion.
First quarter Tysabri revenues came in at $286 million, up 14% from the prior-year period. Global in-market net revenues of Tysabri, which is partnered with Elan Corp. (ELN - Snapshot Report), came in at $399 million (up 14%) in the first quarter of 2012. Tysabri global revenues consisted of US revenues of $201 million and Rest of the World (ROW) revenues of $198 million.
Meanwhile, Biogen’s lead MS product Avonex posted first quarter revenues of $662 million (up 3%). However, unfavorable distribution channel dynamics impacted Avonex’s global unit demand by 4%.
Agreement of Estimate Revisions
Of the 6 analysts following the stock, 2 analysts revised their second quarter estimate upward, while none of the analysts have trimmed their estimates in the last 30 days. There were no revisions during the last 7 days. We believe that Tysabri will continue its strong performance in the second quarter and this has led to the upward estimate revisions by analysts.
For 2012, there has been a downward revision with 1 analyst reducing estimates in the last 30 days. None of the analysts revised their 2012 estimates in the last 7 days.
Magnitude of Estimate Revisions
The magnitude of revisions is modest over the last 30 days. The Zacks Consensus Estimate for the second quarter of 2012 increased a penny to $1.56 per share in the last 30 days. The Zacks Consensus Estimate for 2012 declined by a cent to $6.15 per share in the past 30 days. Biogen expects earnings to exceed $6.15 per share in 2012.
In the last 7 days, there was no change in the Zacks Consensus Estimate for the second quarter of 2012 and full year 2012.
Biogen’s has delivered a positive earnings surprise in two of the last four quarters. The company recorded a maximum of 3.97% in the third quarter of 2011. In the first quarter of 2012, the company delivered a negative earnings surprise of 3.47%. On average, the earnings surprise stood at 0.09%.
We currently have a Neutral recommendation on Biogen, which carries a Zacks #2 Rank (short-term Buy rating). Key products, Avonex and Tysabri, should continue contributing significantly to revenues. BG-12 should help drive long-term growth.
Please login to Zacks.com or register to post a comment.